Literature DB >> 31720401

Prognostic factors in patients with miliary tuberculosis.

Kentaro Wakamatsu1, Nobuhiko Nagata2, Hiroyuki Kumazoe3, Satosi Honjyo4, Makiko Hara1, Aiko Nagaoka1, Naotaka Noda1, Kouji Okamura1, Kenji Kawatoko1, Mizuko Ose1, Erika Yamada1, Takashi Akasaki1, Sanae Maki1, Shinji Ise1, Miiru Izumi1, Masayuki Kawasaki1.   

Abstract

BACKGROUND AND
PURPOSE: Acute respiratory distress syndrome (ARDS) complication has long been considered a factor associated with poor prognosis in patients with miliary tuberculosis. However, few reports exist on the prognostic factors of miliary tuberculosis including those complicating ARDS. SUBJECTS AND METHODS: We retrospectively examined prognoses and other clinical information obtained from medical records of a total of 68 patients diagnosed with miliary tuberculosis. Clinical findings were compared between patients who died within three months (non-survivor group) and those who survived beyond three months (survivor group), and risk factors for death within three months of diagnosis were examined using logistic regression analysis.
RESULTS: Fifteen of 68 patients diagnosed with miliary tuberculosis died within three months. Most patients were aged 60 years or older (63 patients; 91.2%), with a peak in the 80 s (32 patients; 47.1%). Of the 68 patients with miliary tuberculosis, 13 (19%) had ARDS. The risk of death within three months increased with increasing age and ARDS onset during the disease course. The results of multivariate analysis revealed that, in addition to age (odd ratio (OR): 15.5) and the presence/absence of ARDS (OR: 12.0), consciousness disturbance (OR: 81.53) and high BUN levels (OR: 5.71) were independent factors for death within three months.
CONCLUSION: In patients with miliary tuberculosis, old age, ARDS, consciousness disturbance, and high BUN levels were factors associated with poor prognosis.
© 2018 The Authors. Published by Elsevier Ltd.

Entities:  

Keywords:  ARDS; Miliary tuberculosis; Old age; Prognosis

Year:  2018        PMID: 31720401      PMCID: PMC6830168          DOI: 10.1016/j.jctube.2018.07.001

Source DB:  PubMed          Journal:  J Clin Tuberc Other Mycobact Dis        ISSN: 2405-5794


Background

Miliary tuberculosis is a fatal disease caused by hematogenous dissemination of Mycobacterium tuberculosis infection. It is also a rare cause of acute respiratory distress syndrome (ARDS). In many cases, the prognosis of miliary tuberculosis can be improved by introducing effective anti-tuberculosis agents; however, elderly patients and patients with ARDS are likely to suffer a poor prognosis. Only a few reports have described ARDS associated with miliary tuberculosis, with mortality reported to be 33–100% [1], [2], [3], [4], [5], [6], [7], [8], [9]. Moreover, due to poor prognoses, few cases have been reported in which treatment was found to be effective in improving serious conditions [2], [3], [4], [5], [6], [10], [11]. Furthermore, in elderly patients with tuberculosis, older age is considered a risk of mortality, as it relates to decreased function of pulmonary epithelial cells, increased comorbidities, delay in diagnosis due to decreased cognitive ability of patients themselves as well as increased atypical symptoms, and progression of disease state [12]. Many reported studies to date are from high-prevalence countries, targeting relatively young subjects, and few studies have been conducted in elderly patients with tuberculosis. In recent years, a considerably high proportion of patients with tuberculosis in Japan have characteristically been older patients. In this study, we examined prognostic factors in a population of miliary tuberculosis patients including those with ARDS, which predominantly comprised elderly patients.

Methods

Patients

Over a period of 22 years (January 1, 1994–October 1, 2016), 2293 patients were hospitalized at the National Hospital Organization Omuta Hospital with the diagnosis of tuberculosis. Of these, 70 patients were diagnosed with miliary tuberculosis. Two patients who did not undergo chest CT were excluded from analysis. All patients who died due to tuberculosis did not survive beyond three months. Therefore, the remaining 68 patients were divided into those who survived longer than three months (survivor group: n = 53) and those who died within three months of diagnosis (non-survivor group: n = 15). The following clinical information at hospitalization was collected from medical charts: age, sex, history of smoking, alcohol intake, underlying diseases, symptoms, performance status (PS), microbiological data (including the drug sensitivity pattern of M. tuberculosis isolates), PaO2/FiO2 ratio, laboratory findings, time from onset to admission, time from admission to anti-tuberculosis therapy, time from onset to anti-tuberculosis therapy, length of hospital stay, presence or absence of ARDS, and mechanical ventilation. Consciousness disturbance was defined as that with the Glasgow Coma Scale (GCS) of 12 or less.

Diagnosis of miliary tuberculosis

Miliary tuberculosis was diagnosed by one radiologist and two respiratory physicians, based on the observation of randomly distributed, uniformly sized diffuse bilateral nodules on chest CT. A definitive diagnosis of tuberculosis was made when at least one of the following three criteria was met: (1) positive acid-fast bacilli (AFB) smear and/or culture for M. tuberculosis from clinical specimens such as sputum, bronchial lavage fluid, pleural fluid, urine, and bone marrow aspirate; (2) histopathological identification of a tuberculosis granuloma in biopsied tissues of lung, pleura and/or bone marrow; or (3) clinical and radiological improvement after anti-tuberculosis treatment.

Diagnosis of ARDS

ARDS was diagnosed according to the Berlin definition of ARDS, based on chest x-ray and chest CT findings and the PaO2/FiO2 ratio after having excluded all differential diagnoses, such as heart failure, pneumonia, pulmonary haemorrhage, acute interstitial lung disease, and drug reactions [13].

Statistical analysis

Age, PS, platelets, CRP, ALP, total bilirubin, and number of days from hospitalization to the initiation of anti-tuberculosis treatment were comparatively examined between the case group (i.e., patients who died within three months of diagnosis) and the control group (i.e., survivors). Statistical tests were performed using the Wilcoxon rank sum (Mann–Whitney) test. With respect to white blood cell count, neutrophils, AST, ALT, LDH, BUN, creatinine, number of days from onset to hospitalization, and number of days from onset to the initiation of anti-tuberculosis treatment, geometric mean values were comparatively examined between the two groups. In the case of 0 days, logarithmic conversion was performed as 0.1 days. Next, using the case-control study method, risk factors for death within three months of diagnosis were examined. Based on results from previous studies, old age and ARDS onset were suspected to be strongly associated with the risk of death within three months. Since the present study also yielded similar results (described in the following section), analyses of other associated factors were constantly adjusted for age and presence/absence of ARDS, and odds ratios for each factor were obtained using logistic regression analysis. Furthermore, in order to assess which of the examined factors were strongly associated, clinically relevant factors with a p value < 0.1 in the analysis adjusted for presence/absence of ARDS were incorporated as the first explanatory variables, and thereafter, variables were selected using the stepwise method.

Results

Demographic data and clinical characteristics (Table 1)

The median age of the 68 patients with miliary tuberculosis (18 men and 50 women) was 83.0 years (range, 27–93 years). Most patients were aged 60 years or older (63/68; 91.2%), with a peak in the 80 s (32/68; 47.1%). Ten patients (15%) had a history of smoking, and 8 patients (12%) consumed alcohol. There were 102 underlying diseases in 57 patients: dementia (16), liver disease (8), diabetes (18), connective tissue disease with steroid treatment (9), renal disease (7), heart disease (15), cerebrovascular disease (12), aortic aneurysm (3), neuromuscular disease (3), and malignancy (11). Eight patients (11.8%) had a history of tuberculosis. Symptoms were fever (51/68, 75%), dyspnea (20/68, 29%), cough (19/68, 28%), sputum (14/68, 21%), loss of appetite (44/68, 65%), general malaise (45/68, 66%), consciousness disturbance (8/68, 12%) and lumbar pain (7/68, 10%). The median (range) PS was 3 (1–4). Of the 68 patients with miliary tuberculosis, 13 patients (19%) had ARDS; 11 patients had already developed ARDS at the time of first visit, and the other two developed ARDS during hospitalization.

Diagnostic findings

Among 26 patients showing only bilateral diffuse nodules on chest CT, 8 had pleural effusion (Fig. 1A). Among 29 patients showing partially fused nodules as well as infiltrations, in addition to bilateral diffuse nodules, 11 had pleural effusion (Fig. 1B). Among 13 patients who fell under the criteria for ARDS imaging diagnosis and showed ground-glass opacities / infiltrations in the entire lungs in addition to bilateral diffuse nodules, 3 had pleural effusion (Fig. 1C).
Fig. 1

Chest computed tomographic scans showed three patterns: only diffuse nodules exhibiting a random distribution (A); diffuse nodules exhibiting a random distribution with infiltrations (B); and diffuse nodules exhibiting a random distribution with ground glass opacities (C).

Chest computed tomographic scans showed three patterns: only diffuse nodules exhibiting a random distribution (A); diffuse nodules exhibiting a random distribution with infiltrations (B); and diffuse nodules exhibiting a random distribution with ground glass opacities (C). A definitive diagnosis of tuberculosis was made according to the above-mentioned criteria; 63 patients (93%) were ultimately verified to have M. tuberculosis. Of these, 49 had AFB smear-positive clinical specimens during hospitalization, 2 had positive sputum samples by PCR only, and 1 had PCR-positive sputum and bone marrow biopsy tissue showing epithelioid granulomas. Of the AFB smear positive patients, 42 had a positive–PCR for M. tuberculosis (MTb) initially. Another 7 patients had a negative–PCR for MTb in the initial investigation, but culture was subsequently positive. The remaining 11 patients had positive cultures during follow-up. In all cases, the presence of M. tuberculosis was verified using specimens form the respiratory system or respiratory samples (sputum, fluid from endotracheal tube suction, and bronchial lavage fluid). Moreover, 24 patients also had M. tuberculosis culture-positive extrapulmonary specimens (urine, 8; pleural effusion, 6; gastric effusion, 5; blood, 2; and scrotal pus, 12). Subsequently, three patients were confirmed to have tuberculosis by histopathological examination of biopsy tissue (transbronchial biopsy, 1; bone marrow biopsy, 2). As for the remaining two patients, clinical diagnosis was ultimately obtained; these patients had a fever of ≥ 38 °C, and as antibiotics administered for ≥1 week were ineffective, they were referred to our hospital. At the initial visit, one showed only nodules on chest CT, and another showed infiltrations in addition to nodules. Both patients showed improvements in clinical course and imaging findings after treatment with anti-tuberculosis agents was initiated. Based on these courses, the two patients were diagnosed with miliary tuberculosis. The drug susceptibility test was performed with 57 isolates of M. tuberculosis. Of these, 49 isolates (86%) were found to be susceptible to all anti-tuberculosis agents (isoniazid [H], rifampicin [R], ethambutol [E], pyrazinamide [Z], cycloserine, para-aminosalicylic acid [PAS], ethionamide, ofloxacin, streptomycin [S], kanamycin, and enviomycin). On the other hand, the remaining 8 strains (14%) were resistant to at least one agent (3 to H, 1 to S, 3 to E, and 1 to H and S). The numbers of days from onset to hospitalization, from hospitalization to treatment, and from onset to treatment were 37 days (range, 3–361 days), 2 days (range, 0–9 days), and 41 days (range, 3–364 days), respectively.

Hospital course and prognostic factors

Anti-tuberculosis agents were administered to 67 of 68 patients. One patient died on the second day of hospitalization due to ill condition; therefore, no agent was administered. Sixteen patients received additional treatment with HRZE, 6 with HRZS, 7 with HRS, 33 with HRE, 1 with HRZE and LVFX, 1 with HRE and LVFX, one with HRES, one with HR, and one with H and CFLX (She was treated with injections because of poor general condition. CFLX was used instead of LVFX which had not been released as injection preparation in Japan at that time.). INH resistance was detected in 4 cases and treatment was changed to LVFX in 3 cases and TH in 1 case. The median time lag from hospitalization to anti-tuberculosis agent administration was 2 days (range, 0–9 days), with no difference between survivors and non-survivors. Fifteen of 68 patients died due to tuberculosis, with a mortality rate of 22.1%. Of the 15 patients, 6 had ARDS. Compared to the mortality rate of 16% among patients without ARDS, the mortality rate was 46.2% among patients who developed ARDS. With regard to patient characteristics, the risk of death within three months increased with increasing age; however, no steady relationship was observed between the risk of death within three months and sex, smoking history, or alcohol intake. The risk of death within three months also increased with worsening PS. Moreover, ARDS, liver dysfunction, and consciousness disturbance were also associated with an increase in the risk of death within three months. Laboratory findings revealed that an increase in BUN levels was associated with an increase in the risk of death within three months (Table 2). Furthermore, in order to assess which factors were strongly associated, factors with a p value <0.1 (age, PS, ARDS onset, liver dysfunction, consciousness disturbance, and BUN) were incorporated as the initial explanatory variables. In the subsequent examination by the stepwise method, age, ARDS onset, consciousness disturbance, and BUN were four factors that remained significant (Table 3).
Table 2

Comparisons of demographic, clinical, and laboratory characteristics between patients with miliary tuberculosis who died within three months (non-survivors) and who survived longer than three months (survivors).

ParametersSurvivors (n = 53)Non-survivors (n = 15)Crude odds ratio95%CIp-valueAdjusted* odds ratio95%CIp-value
Lower limitUpper limitLower limitUpper limit
Age (years)≤721303.88†1.589.55p for trend = 0.0038.14†1.9833.48p for trend = 0.004
73–78110
79–85156
≥86149
SexFemale37131.00Reference1.00Reference
Male1620.360.071.760.2060.430.072.600.357
Smoking historyAbsence45111.00Reference0.4651.00Reference0.287
Presence731.750.397.892.750.4317.72
Unknown11
Alcohol intakeAbsence46121.00Reference1.00Reference
Presence621.280.237.150.7801.130.158.520.904
Unknown11
PS1801.00Reference1.00Reference
2101
31533.600.3438.300.2883.750.2949.030.313
420119.901.1684.470.0367.640.7182.150.093
p for trend = 0.017p for trend = 0.076
SmearNegative1721.00Reference1.00Reference
Positive36133.070.6215.150.1691.810.3010.990.518
Drug sensitivity pattern0**37120.468 (Fisher's exact test)
1***70
2****10
N/A83
PaO2/FiO2ratio52.9 -1371.00Reference1.00Reference
309 -2650.360.091.350.1280.850.0611.150.900
357 -200.400.081.870.2441.610.1025.160.736
378 -123
p for trend = 0.191p for trend = 0.610
PCRNegative1421.00Reference1.00Reference
Positive39111.970.3910.030.4120.970.146.690.979
N/A02
MGITNegative800.188 (Fisher's exact test )
Positive3611
N/A94
CultureNegative1011.00Reference1.00Reference
Positive43143.260.3827.740.2801.560.1417.710.719
ARDS onsetAbsence4691.00Reference1.00Reference
Presence764.381.1916.130.02615.342.13110.250.007
Underlying diseaseAbsence1100.105 (Fisher's exact test )
Presence4215
Heart diseaseAbsence4491.00Reference1.00Reference
Presence963.260.9311.460.0662.640.6111.480.195
DiabetesAbsence39111.00Reference1.00Reference
Presence1441.010.283.710.9841.830.369.260.464
DementiaAbsence41111.00Reference1.00Reference
Presence1241.240.334.620.7460.300.051.780.187
MalignancyAbsence44131.00Reference1.00Reference
Presence920.750.143.930.7358.090.47139.670.150
Cerebrovascular diseaseAbsence42141.00Reference1.00Reference
Presence1110.270.032.310.2330.200.021.980.171
Renal diseaseAbsence50111.00Reference1.00Reference
Presence346.061.1831.030.0314.930.6239.430.132
Liver diseaseAbsence49121.00Reference1.00Reference
Presence433.060.6015.550.17712.611.03154.210.047
Connective tissue disease with steroid treatmentAbsence45141.00Reference1.00Reference
Presence810.400.053.500.4090.580.056.250.657
AneurysmAbsence50151.000 (Fisher's exact test )
Presence30
Neuromuscular diseaseAbsence50151.000 (Fisher's exact test)
Presence30
Symptoms
Fever (≥38 °C)Absence1341.00Reference1.00Reference
Presence40110.890.243.290.8661.250.256.230.785
CoughAbsence36131.00Reference1.00Reference
Presence1720.330.071.610.1690.580.093.660.562
SputumAbsence41131.00Reference1.00Reference
Presence1220.530.102.660.4370.880.136.050.895
DyspneaAbsence4081.00Reference1.00Reference
Presence1372.690.828.870.1031.470.297.350.637
Loss of appetiteAbsence2221.00Reference1.00Reference
Presence31134.610.9422.530.0594.190.7024.960.116
General malaiseAbsence2031.00Reference1.00Reference
Presence33122.420.619.650.2092.070.4210.050.369
Consciousness disturbanceAbsence48121.00Reference1.00Reference
Presence532.400.5011.480.2739.250.82104.240.072
Lumbar painAbsence47141.00Reference1.00Reference
Presence610.560.065.050.6052.320.1535.660.545
Lymphocyte count2.2-1391.00Reference1.00Reference
416-1320.220.041.230.0850.031.901.230.170
634.5-1330.330.071.520.1560.124.251.520.702
915.2-1410.100.010.930.0430.022.490.930.220
p for trend = 0.024p for trend = 0.220
Platelet count2.9-1381.00Reference1.00Reference
15.3-1440.460.111.920.2890.400.072.250.300
23.3-1330.190.040.830.0270.390.072.160.027
32.1-130
p for trend = 0.025p for trend = 0.262
CRP0.21-1431.00Reference1.00Reference
2.58-1210.390.044.250.4390.730.0510.590.820
5.23-1331.080.186.320.9351.810.2314.380.575
8.97-1482.670.5812.190.2063.180.4920.810.227
p for trend = 0.112p for trend = 0.183
Alb1.5-17101.00Reference1.00Reference
2.55-1730.300.071.290.1050.850.145.310.866
3.05-1720.200.041.050.0570.250.041.580.141
Missing values20p for trend = 0.035p for trend = 0.149
BUN7-1301.00Reference1.00Reference
13-91
14-1634.130.3943.380.2381.490.1218.550.758
21-151116.131.88138.470.0116.610.5973.410.124
p for trend = 0.004p for trend = 0.067
Cr0.25-1321.00Reference1.00Reference
0.54-1410.460.05.70.5500.150.02.80.201
0.63-1063.900.623.60.1380.770.18.10.829
0.87-1662.440.414.20.3210.570.15.20.618
p for trend = 0.128p for trend = 0.881
GOT13-1721.00Reference1.00Reference
29-1841.890.3111.680.4942.080.2815.290.474
41-1883.780.7020.380.1224.110.4934.330.192
Missing values01p for trend = 0.102p for trend = 0.188
GPT3-1431.00Reference1.00Reference
17-2020.470.073.170.4350.230.031.960.180
30-1992.210.509.690.2933.520.3733.680.274
Missing values01p for trend = 0.173p for trend = 0.173
LDH125-1741.00Reference1.00Reference
205-1810.240.022.330.2170.110.011.310.081
261-1892.130.558.210.2740.790.125.110.807
Missing values01p for trend = 0.188p for trend = 0.927

*: Adjusted for age and presence/absence of ARDS. Odds ratios for age and presence/absence of ARDS were only adjusted for other factors mutually. †: Odds ratio for each increase in age group was obtained, when patients were divided into three groups by age.

**: Sensitive to all anti-tuberculosis agents.

***: Resistance to at least one anti-tuberculosis agent.

****: Resistance to two anti-tuberculosis agents.

ARDS: acute respiratory distress syndrome, PS: Performance Status, AFB: Acid-fast bacteria, BMI: body mass index, WBC: white blood cell, Alb: Albumin, CRP: C-reactive protein, Cr: creatinine, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase.

Table 3

Relationships between clinical factors and the risk of death within three months of miliary tuberculosis diagnosis: multivariate analysis.

ParametersSurvivors (n = 53)Non-survivors (n = 15)Adjusted odds ratio†95% Confidence interval
P = value
Lower limitUpper limit
Age (years)≤7213015.5‡1.79134.57p for trend = 0.013
73–78110
79–85156
≥86149
ARDS onsetAbsence4691.00Reference
Presence761211410.050
Consciousness disturbanceAbsence48121.00Reference
Presence5381.531.265258.400.038
BUN7-1305.71‡1.1328.77p for trend = 0.035
13-91
14-163
21-1511

†: Four variables in the table were selected with age, presence/absence of ARDS during the disease course, PS, presence/absence of consciousness disturbance, and presence/absence of liver disease as explanatory variables with a removal probability of 0.1 by backward elimination.

‡: For age and BUN levels, odds ratios for each increase in group were obtained. ARDS: acute respiratory distress syndrome.

Baseline characteristics of patients with miliary tuberculosis (n = 68). Data are presented as median (range) or number (%). ARDS: acute respiratory distress syndrome; PS:performance status; AFB: acid-fast bacteria; BMI: body mass index. Comparisons of demographic, clinical, and laboratory characteristics between patients with miliary tuberculosis who died within three months (non-survivors) and who survived longer than three months (survivors). *: Adjusted for age and presence/absence of ARDS. Odds ratios for age and presence/absence of ARDS were only adjusted for other factors mutually. †: Odds ratio for each increase in age group was obtained, when patients were divided into three groups by age. **: Sensitive to all anti-tuberculosis agents. ***: Resistance to at least one anti-tuberculosis agent. ****: Resistance to two anti-tuberculosis agents. ARDS: acute respiratory distress syndrome, PS: Performance Status, AFB: Acid-fast bacteria, BMI: body mass index, WBC: white blood cell, Alb: Albumin, CRP: C-reactive protein, Cr: creatinine, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase. Relationships between clinical factors and the risk of death within three months of miliary tuberculosis diagnosis: multivariate analysis. †: Four variables in the table were selected with age, presence/absence of ARDS during the disease course, PS, presence/absence of consciousness disturbance, and presence/absence of liver disease as explanatory variables with a removal probability of 0.1 by backward elimination. ‡: For age and BUN levels, odds ratios for each increase in group were obtained. ARDS: acute respiratory distress syndrome.

Discussion

Traditionally, miliary tuberculosis has been commonly observed as a type of primary tuberculosis. Previous reports on the prognosis of patients with miliary tuberculosis, including, especially, those with ARDS, have noted a high prevalence in young people in their 20 s, with many reporting the mean age ranging from 40 to 60 years [1], [2], [3], [4], [5], [6], [8], [9], [10], [11], [12], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23]. In Japan, a publication from more than 20 years ago reported a mean (±SD) age of 45.3 (±19.3) years [7]. However, in recent years, a remarkably high proportion of the population of patients with tuberculosis in Japan is characteristically elderly, while having a lower proportion of HIV co-infection and multidrug-resistant tuberculosis; a similar trend is starting to appear in the age distribution of extrapulmonary tuberculosis patients [24]. The results of the present study reflected this trend, as those aged 80 years or higher were highest in number (41/68 patients; 60%). In this regard, this study reports valuable findings that shed light on the current status of miliary tuberculosis in Japan. According to previous studies, ARDS develops in association with miliary tuberculosis at a rate of 16–24% [2], [3], [6]. In the present study as well, ARDS was observed at a similar rate of 19% in patients with miliary tuberculosis. The rate of disease-specific deaths in patients with miliary tuberculosis with ARDS is reportedly high, at 30–90% [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11]. In the present study, disease-specific mortality in patients with ARDS was 46.2%, which was significantly higher compared to 16% in patients who did not develop ARDS. These findings suggest the need for a comprehensive study, when considering the prognosis of miliary tuberculosis, that includes patients with ARDS. Reports on the prognosis of miliary tuberculosis consistently suggest ARDS to be associated with poor prognosis [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11]. Other reported prognostic factors include old age [16], immunodeficiency [16], [19], diabetes [22], delayed discovery [15], [17], psychiatric disorders [8], [20], elevated liver enzymes [15], renal dysfunction [15], [19], malnutrition [15], [21], thrombocytopenia [20], [22], and greater extent of ground glass opacity [23], although no consistent outcomes have been obtained with regard to this aspect. Many previous reports are from high-prevalence countries, with high proportions of subjects being relatively young patients; few reports mention old age as a prognostic predictor [16]. Meanwhile, one of the characteristics of the tuberculosis population in Japan is that the number of elderly patients is remarkably high, and many reports suggest old age as a prognostic predictor [25], [26], [27]. In our patients, in addition to the presence/absence of ARDS, age was considered to be strongly associated with the risk of death within three months. Therefore, we conducted analyses by constantly adjusting for age and presence/absence of ARDS to obtain odds ratios for each factor. As a result, ARDS onset, old age, PS, liver dysfunction, consciousness disturbance, and high BUN levels were identified as risk factors for death within three months. We further examined these factors using the stepwise method to assess those showing strong associations, and found ARDS onset, old age, consciousness disturbance, and high BUN levels to be significant factors. With regard to the causes and extent of consciousness disturbance, many aspects remain unclear, as the present study was retrospective in nature. While our subjects likely included those with meningitis and brain tuberculosis, head CT or MRI examinations were not performed, as the condition of patients presenting with consciousness disturbance was poor, with the GCS of 12 or less. As for high BUN levels, given that no steady relationships were observed between the risk of death within three months and presence/absence of renal disease or serum creatinine levels, our observation might have reflected dehydration tendencies or hypercatabolism. In Japan, nutritional status is often reported as a prognostic factor for tuberculosis. However, the present study did not find nutritional status to be an independent prognostic predictor. This could be explained by the fact that the nutritional condition of patients with miliary tuberculosis had already deteriorated somewhat at the time of hospital admission, and was thus unlikely to serve as a predictor of prognosis. Prognostic factor might be not specific to miliary TB: old age, ARDS, consciousness disturbance and high BUN levels would be expected to be predictors of mortality in any condition. There are some limitations to this study. First, this study was conducted at a single center with a small sample size. In particular, the number of patients with ARDS was quite low. Data on co-morbidities from clinical records were incomplete, but there was no reason to assume a systematic bias for missing information, since they were obtained from the records. Moreover, as the present study used a retrospective design, the degree of consciousness disturbance and the extent of dementia were unclear, and the causes of underlying diseases including renal disease and liver disease were unknown. In summary, the present study examined prognostic factors in patients with miliary tuberculosis including those with ARDS in Japan, and revealed that ARDS onset, old age, presence/absence of consciousness disturbance, and high BUN levels are independent poor prognostic factors.

Conclusion

In patients with miliary tuberculosis, the complication of ARDS was observed in 19%. Old age, ARDS, consciousness disturbance, and high BUN levels were factors associated with poor prognosis.

Ethical considerations

The present study was approved by the Ethics Committee of the National Hospital Organization at Omuta Hospital. The IRB approval number was 29-43.

Availability of data

There are no data other than those included in this article.

Competing interests

The authors declare that they have no competing interests.

Funding

The authors declare that they have no funding.

Author contributions

KW conceived the idea and designed the tool together with NN and HK. SH, MH, AN, NN, KO, KK, MO, EY, TA, SM, SI, MI and MK were involved in the implementation. All authors reviewed and approved the final version of the manuscript.
Table 1

Baseline characteristics of patients with miliary tuberculosis (n = 68).

ParametersResultsParametersResults
Number of patients68AFB-positive sputum: positive/total (%)
Age, years (range)83 (27–93)Smear49/68 (71%)
Sex: male/female18/50PCR50/66 (76%)
Smoking history: current/former/never0/10/56MGIT47/55 (85%)
Alcohol intake: presence/absence8/59Culture57/68 (84%)


Underlying diseaseCulture of AFB in specimens: positive/total (%)
Heart disease15 (22%)Urine8/31 (26%)
Diabetes18 (27%)Gastric effusion5/9 (56%)
Dementia16 (24%)Scrotal pus12/37 (32%)
Malignancy11 (16%)Blood2/20 (10%)
Cerebrovascular disease12 (18%)Cerebrospinal fluid0/8 (0%)
Renal disease7 (10%)Bronchial lavage fluid4/8 (50%)
Liver disease7 (10%)Pleural effusion6/12 (50%)
Connective tissue disease with steroid treatment9 (13%)Ascites fluid0/0 (0%)


Aneurysm3 (4%)Histopathological examination positive/total (%)
Neuromuscular disease3 (4%)Transbronchial biopsy6/8 (75%)
None11 (16%)Bone marrow biopsy9/14 (64%)
ARDS onset13 (19%)Body mass index (kg/m2)18.8 (12.6–26.5%)
SymptomsThe period from onset to hospitalization, days (range)37 (3–361)
Fever (≥38 °C)51 (75%)
Cough19 (28%)The period from hospitalization to anti-tuberculosis treatment, days (range)2 (0–9)
Sputum14 (21%)
Dyspnea20 (29%)The period from onset to anti-tuberculosis treatment, days (range)41 (3–364)
Loss of appetite44 (65%)
General malaise45 (66%)Length of hospital stay, days (range)102 (2–547)
Consciousness disturbance8 (12%)
Lumbar pain7 (10%)
PS (median)3 (1–4%)

Data are presented as median (range) or number (%).

ARDS: acute respiratory distress syndrome; PS:performance status; AFB: acid-fast bacteria; BMI: body mass index.

  27 in total

1.  Clinical characteristics of 110 miliary tuberculosis patients from a low HIV prevalence country.

Authors:  S F Hussain; M Irfan; M Abbasi; S S Anwer; S Davidson; R Haqqee; J A Khan; M Islam
Journal:  Int J Tuberc Lung Dis       Date:  2004-04       Impact factor: 2.373

2.  Nutritional deficit as a negative prognostic factor in patients with miliary tuberculosis.

Authors:  D K Kim; H J Kim; S-Y Kwon; H-I Yoon; C-T Lee; Y W Kim; H S Chung; S K Han; Y-S Shim; J-H Lee
Journal:  Eur Respir J       Date:  2008-05-28       Impact factor: 16.671

3.  Clinical relevance of ground glass opacity in 105 patients with miliary tuberculosis.

Authors:  Jaehee Lee; Jae Kwang Lim; Hyewon Seo; So Yeon Lee; Keum Ju Choi; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Chang Ho Kim
Journal:  Respir Med       Date:  2014-04-13       Impact factor: 3.415

4.  Acute respiratory distress syndrome caused by miliary tuberculosis: a multicentre survey in South Korea.

Authors:  K Lee; J H Kim; J H Lee; W-Y Lee; M S Park; J Y Kim; K C Kim; M-G Lee; K-S Jung; Y S Kim; Y M Shin; Y Koh
Journal:  Int J Tuberc Lung Dis       Date:  2011-08       Impact factor: 2.373

5.  Development and validation of a tuberculosis prognostic score for smear-positive in-patients in Japan.

Authors:  N Horita; N Miyazawa; T Yoshiyama; T Sato; M Yamamoto; K Tomaru; M Masuda; K Tashiro; M Sasaki; S Morita; T Kaneko; Y Ishigatsubo
Journal:  Int J Tuberc Lung Dis       Date:  2013-01       Impact factor: 2.373

6.  Disseminated tuberculosis. A study of 62 cases.

Authors:  S Prout; S R Benatar
Journal:  S Afr Med J       Date:  1980-11-22

7.  Epidemiological, clinical, laboratory findings, and outcomes of disseminated tuberculosis in Tehran, Iran.

Authors:  Mehrdad Hasibi; Mehrnaz Rasoulinejad; Seyed-Mahmoud Eshagh Hosseini; Parastoo Davari; Azadeh Sahebian; Patricia Khashayar
Journal:  South Med J       Date:  2008-09       Impact factor: 0.954

Review 8.  [Prognosis of patients with tuberculosis].

Authors:  Nobuyuki Horita; Naoki Miyazawa; Takashi Yoshiyama; Yoshiaki Ishigatsubo
Journal:  Kekkaku       Date:  2013-06

9.  Adult respiratory distress syndrome associated with miliary tuberculosis.

Authors:  R A Dyer; W A Chappell; P D Potgieter
Journal:  Crit Care Med       Date:  1985-01       Impact factor: 7.598

10.  Experience with ARDS caused by tuberculosis in a respiratory intensive care unit.

Authors:  Ritesh Agarwal; Dheeraj Gupta; Ashutosh N Aggarwal; Digamber Behera; Surinder K Jindal
Journal:  Intensive Care Med       Date:  2005-07-09       Impact factor: 17.440

View more
  4 in total

1.  Clinical and radiologic characteristics of radiologically missed miliary tuberculosis.

Authors:  Jooae Choe; Kyung Hwa Jung; Joung-Ha Park; Sung-Han Kim; Mi Young Kim
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

2.  Miliary tuberculosis in a paediatric patient with psoriasis.

Authors:  Jacob Kilgore; Jonathon Pelletier; Bradford Becken; Stephen Kenny; Samrat Das; Lisa Parnell
Journal:  BMJ Case Rep       Date:  2021-03-09

3.  Corticosteroid-induced exacerbation of cryptic miliary tuberculosis to acute respiratory distress syndrome: A case report.

Authors:  Minji Song; Sung Jin Kim; Jin Young Yoo
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

4.  Clinical analysis of pregnancy complicated with miliary tuberculosis.

Authors:  Kaige Wang; Donghua Ren; Zhixin Qiu; Weimin Li
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.